Suzhou Ribo Life Science Co. Ltd. (瑞博生物)

An IPO opening for Asian biotechs 

Early 2024 dealmaking activity also included Roche-MOMA, Avenzo-Allorion, AbbVie-Umoja and Boehringer-3T

Plus: Arrowhead trades up as $450M follow-on extends runway and updates from Remix, CG Oncology, Agios, Boehringer-Ribo, Enyo

Plus Opdivo-Yervoy combination misses as renal cell carcinoma adjuvant therapy, and updates from Novasenta, ShenZhen and more

A dozen candidates built on four gene silencing approaches have entered the clinic

Transcenta rounds out year with $105M crossover roundTranscenta Holding Ltd. raises $105 million in a crossover round led by China Structural Reform Fund. New investors Country Garden Venture

How professors are joining China’s drive toward innovative biotech